Showing results (191-200 of 722) with videos related to

Sort By:
Pageof 73
The Lancet. Haematology|December 31, 2021
Symptom burden and quality of life in patients with high-risk essential thrombocythaemia and polycythaemia vera receiving hydroxyurea or pegylated interferon alfa-2a: a post-hoc analysis of the MPN-RC 111 and 112 trialsGina L Mazza, Carolyn Mead-Harvey, John Mascarenhas, et al.
The Lancet. Haematology|November 4, 2021
Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1-2 studyToby A Eyre, Anna Schuh, William G Wierda, et al.
The Lancet. Haematology|November 3, 2022
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trialHartmut Goldschmidt, Elias K Mai, Uta Bertsch, et al.
The Lancet. Haematology|September 15, 2022
Postnatal treatment for children with fetal and neonatal alloimmune thrombocytopenia: a multicentre, retrospective, cohort studyThijs W de Vos, Dian Winkelhorst, Valgerdur Árnadóttir, et al.
The Lancet. Haematology|January 15, 2016
Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional studyWalter Ageno, Lorenzo G Mantovani, Sylvia Haas, et al.
The Lancet. Haematology|December 22, 2015
Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trialHarry J Iland, Marnie Collins, Ken Bradstock, et al.
The Lancet. Haematology|December 22, 2015
Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trialUwe Platzbecker, Raymond S M Wong, Amit Verma, et al.
The Lancet. Haematology|December 22, 2015
Efficacy and safety of thalidomide for the treatment of severe recurrent epistaxis in hereditary haemorrhagic telangiectasia: results of a non-randomised, single-centre, phase 2 studyRosangela Invernizzi, Federica Quaglia, Catherine Klersy, et al.
The Lancet. Haematology|December 22, 2015
Analysis of an algorithm incorporating limited and whole-leg assessment of the deep venous system in symptomatic outpatients with suspected deep-vein thrombosis (PALLADIO): a prospective, multicentre, cohort studyWalter Ageno, Giuseppe Camporese, Nicoletta Riva, et al.
The Lancet. Haematology|December 22, 2015
Cardiovascular disease after treatment for Hodgkin's lymphoma: an analysis of nine collaborative EORTC-LYSA trialsMaja V Maraldo, Francesco Giusti, Ivan R Vogelius, et al.
Pageof 73